Can a virtual team of researchers break a 40-year logjam in this rare cancer?
John Carroll
August 25, 2025
When Mac Tichenorβs son Willie died of osteosarcoma at the age of 19 back in 2006, oncologists still relied on a decades-old chemo regimen called MAP β high-dose methotrexate, combined with doxorubicin and cisplatin. Typically, for young patients with the rare bone cancer, it staved off death for a while.
UPDATES ANDΒ NEWS
Radical Collaboration: A Cancer Funder Seeks to Solve the Problem of Siloed Research | Inside Philanthropy
Why some family offices are becoming cancer research’s new bankrollers | Crain Currency
π‘ππΎπΊπ ππ©π³π°πΆπ¨π© π’πΊππΌπΎπ’π Tyler Jacks: βWeβve created a new operating model for collaborative cancer research. | The Cancer Letter
2025 Year in Review: Our Scientific Progress and Clinical Impact
BE PART OF THE MISSION
Stay Informed, Make an Impact
Subscribe
Be the first to hear about cutting-edge research, pioneering projects, and the latest advancements in Break Through Cancer science. Sign up to stay informed.
Give
Your contribution fuels groundbreaking research in some of the most challenging cancers. Every gift accelerates progress. For more information please contact Michaela Forand at MF@breakthroughcancer.org or 1-800-757-9881 ext 2.
